|Other Names||BMP-binding endothelial regulator protein, Bone morphogenetic protein-binding endothelial cell precursor-derived regulator, Protein crossveinless-2, hCV2, BMPER, KIAA1965|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13190a was selected from the N-term region of BMPER. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Inhibitor of bone morphogenetic protein (BMP) function, it may regulate BMP responsiveness of osteoblasts and chondrocytes.|
|Tissue Location||Highly expressed in lung, and brain and also in primary chondrocytes.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Inhibitor of bone morphogenetic protein (BMP) function, it may regulate BMP responsiveness of osteoblasts and chondrocytes.
Funari, V.A., et al. Am. J. Hum. Genet. 87(4):532-537(2010)Heinke, J., et al. Circ. Res. 103(8):804-812(2008)Binnerts, M.E., et al. Biochem. Biophys. Res. Commun. 315(2):272-280(2004)Moser, M., et al. Mol. Cell. Biol. 23(16):5664-5679(2003)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.